ReviewSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026
[The Clinical Application and Development of Tumor Biomarkers in China].
Review in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor biomarkers play an increasingly prominent role in early screening, auxiliary diagnosis, efficacy evaluation, and prognosis assessment, becoming an essential component of the precision oncology system. This article systematically reviews the nearly two-century development history of tumor markers, from early protein-based markers to the genomics era. It focuses on the fundamental principles of standardized application of tumor markers in China, the current laboratory application status, and clinical application recommendations for key cancer types such as lung cancer and liver cancer. Additionally, it delves into multidimensional marker research supported by liquid biopsy technologies, including ctDNA genetic markers, DNA methylation, exosomes, and circulating tumor cells, as well as cutting-edge advancements and clinical translation challenges in areas such as artificial intelligence model construction. This review aims to provide insights for the innovative development and standardized application of tumor markers in China, thereby enhancing the precision of cancer prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.